MedTrace Logo

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

NCT06386263 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2025-10-15

No results posted yet for this study

Summary

Trastuzumab deruxtecan (T-DXd) has been studied in multiple global prospective DESTINY-Breast trials and has a marketing authorization from Health Canada for patients with HER2-positive metastatic breast cancer (mBC) and HER2-low mBC, respectively.

Multiple stakeholders, including clinicians, patients, regulators, and healthcare decision makers, are interested in real-world treatment-related outcomes in order to better represent the effectiveness of therapies in routine care settings.

Conditions

Interventions

DRUG

Trastuzumab deruxtecan

This is a non-interventional, observational study. Patients who are enrolled by their clinician will receive T-DXd per routine clinical practice through the PSP.

Sponsors & Collaborators

Principal Investigators

  • Christine Brezden-Masley · Sinai Health System

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-22
Primary Completion
2025-07-07
Completion
2025-07-07
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06386263 on ClinicalTrials.gov